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Abstract
Human cytomegalovirus (HCMV) is an important human pathogen. It is a leading cause of congenital infection and a
leading infectious threat to recipients of solid organ transplants as well as of allogeneic hematopoietic cell transplants.
Moreover, it has recently been suggested that HCMV may promote tumor development. Both CD4+ and CD8+ T cell
responses are important for long-term control of the virus, and adoptive transfer of HCMV-specific T cells has led to
protection from reactivation and HCMV disease. Identification of HCMV-specific T cell epitopes has primarily focused on
CD8+ T cell responses against the pp65 phosphoprotein. In this study, we have focused on CD4+ and CD8+ T cell responses
against the immediate early 1 and 2 proteins (IE1 and IE2). Using overlapping peptides spanning the entire IE1 and IE2
sequences, peripheral blood mononuclear cells from 16 healthy, HLA-typed, donors were screened by ex vivo IFN-c ELISpot
and in vitro intracellular cytokine secretion assays. The specificities of CD4+ and CD8+ T cell responses were identified and
validated by HLA class II and I tetramers, respectively. Eighty-one CD4+ and 44 CD8+ T cell responses were identified
representing at least seven different CD4 epitopes and 14 CD8 epitopes restricted by seven and 11 different HLA class II and
I molecules, respectively, in total covering 91 and 98% of the Caucasian population, respectively. Presented in the context of
several different HLA class II molecules, two epitope areas in IE1 and IE2 were recognized in about half of the analyzed
donors. These data may be used to design a versatile anti-HCMV vaccine and/or immunotherapy strategy.
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Introduction
Human cytomegalovirus (HCMV) is a member of the
ubiquitous Betaherpesvirinae subfamily, which infects 50–100% of
the adult population[1]. In healthy immunocompetent individuals,
HCMV establishes a life-long asymptomatic latent infection where
intermittent sub-clinical reactivations are successfully controlled by
the immune system. In contrast, in individuals without adequate
immune-mediated control, HCMV infection results in consider-
able morbidity and even mortality. This includes recipients of solid
organ transplants (SOT) or allogeneic-hematopoietic cell trans-
plants (allo-HCT) that are given immunosuppressive treatment
where HCMV is one of the most frequent and clinically relevant
infectious complications[2], [3], [4], [5], [6]. Indeed, most
immunosuppressive strategies include a component that closely
monitors HCMV infection allowing immediate preemptive anti-
viral therapy should HCMV reactivation be detected. Another
important area of HCMV-mediated pathogenicity is that of
congenital HCMV infection. It is the most frequent and important
congenital infection where it can lead to severe developmental
abnormalities and fetal death[7]. Lastly, HCMV has been
implicated in various human cancers[8] with immediate early
(IE) proteins possibly playing a key role in promoting carcinogen-
esis[9]. Thus, a recent study showed significantly improved
survival of glioblastoma patients receiving valganciclovir in
combination with conventional chemotherapy as compared to
patients only receiving chemotherapy[10]. Overall, HCMV is a
significant health burden[11].
How to prevent and/or treat HCMV infection is therefore a
highly relevant medical issue. Current anti-viral drugs such as
ganciclovir and foscarnet have serious adverse effects such as
impaired hematopoietic recovery and nephrotoxicity[12]. Thus,
there is a need for safer and more efficient alternatives. All
components of the adaptive immune system, B cells, CD4+ T
helper cells (Th), and CD8+ cytotoxic T cells (CTLs)[2], [13], [14],
[15], are involved in generating and maintaining anti-HCMV
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immunity, and it is believed that vaccination and/or immuno-
therapy may provide efficient prevention and/or treatment
without side effects[16], [17], [18]. In particular, trials with
adoptive T cell transfer of HCMV-specific T cells to recipients of
allo-HCT have been encouraging[19], [20], [21], [22]. Thus,
adoptive transfer of CD8+ CTLs has been reported to restore
cellular immunity against HCMV in human patients (e.g. [19],
[23]) as well as in a murine model of cytomegalovirus[24]. From
studies of the murine immune system, it is known that CD4+ Th
cell activity is important for maintenance of immunological
memory[25], [26]. That a similar need for CD4+ Th exists in
protection against HCMV is suggested by studies showing that
durable HCMV-specific T cell immunity depends on the presence
of HCMV-specific CD4+ T cells [20], [27], [28], by observations
that specific CD8+ T cells can clear ongoing HCMV infection, but
not establish lasting immunity[27], [28], and by the association of
suppression of CD4+ T cell responses and HCMV disease in HIV
patients[29]. Thus, trials of adoptive T cell therapy should include
both CD4+ and CD8+ T cells specific for HCMV[17].
A particularly promising approach involved the use of a single
peptide-HLA class I tetramer to obtain an anti-HCMV reactive
CD8+ T cell preparation of a single specificity from appropriate
HCMV-seropositive donors[19]. Immediately after preparation,
these mono-specific CD8+ CTLs were transferred to allo-HCT
patients, where they proliferated and showed in vivo activity.
HCMV viremia was reduced in all nine recipients and cleared in
eight of them. No side effects were observed. This suggests that
simple direct epitope-specific adoptive T cell transfer could afford
efficient and safe HCMV protection. In fact, a current phase 2
trial is evaluating a similar approach to select HCMV-specific T
cells, with the aim of preventing reactivation and disease[30]. It is
a reasonable assumption that a multi-epitope approach would be
even more efficient in protecting the host from uncontrolled
HCMV replication since broadening immune reactions to a larger
repertoire of known HCMV-specific T cell epitopes should
multiply and diversify the immune response and stand a better
chance of controlling a virus at any phase of its life cycle thereby
minimizing the risk of viral escape. Furthermore, including CD4+
Th cells recognizing one or more epitopes should contribute
towards maintaining immune memory and protection. Thus, using
a multi-epitope approach should be an advantage[31], [32], [33],
and should be instrumental in enabling specific adoptive T cell
transfer to most, if not all, immunocompromised patients in need
of anti-HCMV prevention and/or therapy.
The purpose of this report is to extend our knowledge of
frequently recognized (i.e. dominant) anti-HCMV-specific CD4
and CD8 epitopes. To this end we have systematically examined
cellular immune responses against proteins encoded by the IE
regulatory genes. These are essential for viral gene expression and
replication[34]. Of particular interest here, IE, early, and late class
genes being expressed in temporal order defines a replicative cycle.
Thus, the first wave is characterized by the transcription of IE
genes, and T cells recognizing IE epitopes should target the first
gene products expressed during reactivation. Interestingly, a study
of heart and lung transplant recipients suggested that T cells
recognizing IE gene products may be crucial for virus control, as
CD8+ T cell reactivity against IE1 protein, but not against the
otherwise immunodominant 65-kDa phosphoprotein (pp65),
correlated with protection from HCMV disease[35].
The most extensively studied IE proteins, the 72 kDa-IE1
protein (IE1) and the 86 kDa-IE2 protein (IE2), are two of several
IE gene products; the IE2 gene is indispensable for viral
replication, and deletion of the IE1 gene reduces viral replica-
tion[36], [37]. Both proteins have previously been found to be
highly immunogenic[15]. In the present study we used overlap-
ping peptides spanning the entire IE1 and IE2 sequences and a
combination of bioinformatics, immunochemistry, and cellular
immunology to identify IE1- and IE2-specific T cell responses in
16 healthy HCMV-reactive donors. The ability to induce CD4+
and CD8+ T cell responses ex vivo and after an in vitro culture was
evaluated with combinations of ELISpot and flow cytometric
intracellular cytokine secretion assays (ICS). Further epitope
characterization and restriction validation of CD4+ and CD8+ T
cell responses was done using bioinformatics prediction tools,
peptide-HLA binding analysis, and HLA class I and II tetramer
staining. Eighty-one CD4+ and 44 CD8+ T cell responses were
identified in the 16 donors, and in many cases the underlying
peptide-specific, HLA-restricted reactivity of these responses were
validated with appropriate peptide-HLA class I or II tetramers.
Many of these specificities were recognized in several different
donors, and may therefore serve as broadly relevant targets for
immune-mediated prevention and/or therapy of HCMV infec-
tion.
Materials and Methods
Donors (and Ethics Statement)
The study of donor immune responses was approved at the
National University Hospital of Copenhagen by ‘‘The Committees
on Biomedical Research Ethics of the Capital Region’’ (Danish:
‘‘De Videnskabsetiske Komiteer for Region Hovedstaden’’) (RH-
3-CT5604) with informed written consent.
Buffy coats were obtained from 16 healthy Danish blood donors
(age 35–65 years). Peripheral blood mononuclear cells (PBMC)
were isolated by density gradient centrifugation using Ficoll-Paque
Plus (GE Healthcare Europe, Brøndby, Denmark), and stored
until use at 2150uC.
Chromosomal DNA was isolated from all donors and typed for
HLA-A/B/C and HLA-DR/DQ/DP using Sequence Based
Typing (Genome Diagnostics, Utrecht, the Netherlands).
Peptides
The primary sequences of the 412 amino acid long IE1 and the
580 amino acid long IE2 from the HCMV isolate AD169 were
obtained from the UniProt database (www.UniProt.org, accession
numbers P13202 (IE1) and P19893 (IE2)). Fifteen amino acid long
peptides overlapping by 10 amino acids spanning the entire IE1
and IE2 protein, a total of 187 peptides (78 IE1 peptides and 109
IE2 peptides), were synthesized. Note that the initial 85 amino
acids of IE1 and IE2, corresponding to fourteen 15mer peptides,
were identical and only represented once in the IE2 peptide pool.
The peptides were used either individually or in pools of IE1
peptides or IE2 peptides.
Peptides were synthesized by standard 9-fluorenylmethyloxy-
carbonyl chemistry and purified by reversed-phase high-perfor-
mance liquid chromatography (purity at least 80%, usually .95%)
(Schafer-N, Copenhagen, Denmark). In addition, pools of 15-
amino acid long overlapping peptides spanning the entire pp65
protein (strain AD169) were obtained from JPT Peptide Technol-
ogies, Berlin, Germany.
Ex vivo Interferon-c ELISpot assay
An interferon-c (IFN-c) ELISpot assay was performed as
previously described[38]. Briefly, PBMCs were thawed, resus-
pended in Xvivo15 (Lonza) supplemented with 5% AB serum
(Invitrogen) – ‘‘complete medium’’, and incubated at 2–56105
cells/well in an anti-IFN-c (mAb1-D1K, MabTech, Nacka
Strand, Sweden)-coated ELISpot plate (MAHAS4510, Merck
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Milipore, Billerica, USA) for 18–24 h in the presence or absence of
peptides at a final concentration of 1 mM. As positive controls, cells
were stimulated with Staphylococcal enteroxin B (SEB, Sigma
Aldrich, St. Louis, USA) at a final concentration of 1 mg/ml. Two
wells without peptide served as negative control. Plate-bound IFN-
c was detected with biotinylated antihuman IFN-c (mAb 7-B6-1,
MabTech, Nacka Strand, Sweden) and developed by addition of
streptavidin conjugated alkaline phosphatase (Streptavidin ALP,
MabTech, Nacka Strand, Sweden) and substrate (AP Conjugate
substrate, Bio-Rad, Hercules, USA). Analysis was done using
ImmunoSpot 5.0.9 software (C.T.L., Shaker Heights, USA).
Observed background range was 0–10 spot forming units
(SFU)/106 PBMC (average 3 SFU/106 PBMC). As others have
noted, there is no consensus on the definition of a positive response
in ELISpot and other assays employed to detect antigen-specific T
cells and antigen-specific T cell responses[39]. We chose 25 SFU/
106 PBMC (negative control subtracted) as a threshold for positive
responses. Peptides eliciting these responses were selected for
subsequent in vitro culture.
Cell cultures
PBMCs. PBMCs were incubated overnight with 1 mM of
peptide in complete medium. At day 2 the cells were harvested,
washed, and plated in new wells with 50 U/ml IL-2. Fresh
medium and IL-2 were added every second day. From day 6, IL-
15 was added every second day. The cells were harvested for
analysis at day 12–14.
Dendritic cells (DCs). In some cases the analysis of HLA
restriction was performed using DCs and HLA-matched allo-
presentation. Briefly, DCs were generated from adherent cells
after 1.5 h incubation of PBMCs at 37uC, 5% CO2. The adherent
cells were cultured for 8–11 days in complete medium supple-
mented with granulocyte-monocyte colony-stimulating factor
(250 U/ml) and IL-4 (500 U/ml). Fresh medium and cytokines
were added every third day. The DCs were activated with tumor
necrosis factor-a (TNF-a) (10 ng/ml), IL-6 (20 ng/ml), IL-1b
(5 ng/ml) and prostaglandin E2 (PGE2) (1 mg/ml) 48 h before use.
All cytokines were purchased from Peprotech, Germany, except
for PGE2, which was purchased from Sigma-Aldrich, Germany.
Intracellular cytokine secretion assay (ICS)
Ex vivo. Thawed PBMCs were resuspended in complete
medium and aliquoted at 16106 cells/well in 96-well round
bottom microtiter plates. Cells were stimulated with or without
various different peptides and peptide pools (1 mM of each peptide)
and costimulatory CD28/49d antibody (1 mg/ml) (Becton Dick-
inson) for 6 h at 37uC, 5% CO2. Brefeldin A (Sigma-Aldrich) was
present for the last 5 h of incubation.
In vitro culture. In vitro cultured PBMCs were harvested,
washed, resuspended in complete medium, and aliquoted at 2–
46105 cells/well. The cells were incubated with relevant single
peptide (1 mM) for 4 h at 37uC, 5% CO2. Brefeldin A was present
for the last 3 h of incubation.
ICS. The cells were subsequently incubated with EDTA (final
concentration 1.4 mM) at RT. Afterwards the cells were
permeabilized (Becton Dickinson Permeabilizing solution 2) and
stained with anti-CD3–allophycocyanin(APC)/Cy7, anti-CD4-
peridinin chlorophyll(PerCp), anti-CD8-APC, anti-CD69-R-phy-
coerythin(PE), and anti-IFN-c-fluorescein isothiocyanate(FITC)
(Biolegend, San Diego, USA). Finally the cells were fixed in 1%
formaldehyde and analyzed by flow cytometry on LSRII (BD
Biosciences).
HLA-matched allo-presentation analysis. Autologous or
HLA-matched allogeneic DCs were pulsed with peptides at a final
concentration of 0.1–0.3 mM and incubated for 90 min at 37uC,
then washed and irradiated (2000 rad). T cells were added,
incubated for 4 h, and analyzed by the protocol for ICS assay
described above.
Tetramer staining
HLA class I tetramers. HLA class I tetramers were
produced as previously described [40]. Briefly, biotinylated
recombinant HLA class I heavy chains were diluted into a
reaction buffer containing 50 mM tris-maleate pH 6.6, 0.1%
Pluronic F86 NF (BASF, a surfactant compatible with cellular use),
an excess of b2-microglobulin (b2m) and peptide, and incubated
for 48 h at 18oC. To tetramerize the resulting peptide-HLA class I
monomers, Streptavidin-PE or Streptavidin-APC (Biolegend, San
Diego, USA) was sequentially added over 60 min at a 1:4 molar
ratio of Streptavidin to peptide-HLA-I monomers. PBMCs were
resuspended in 25 ml PE- and APC-conjugated tetramer and
incubated for 20 min at RT followed by 30 min incubation with
anti-CD3-Pacific blue, anti-CD4-APC/Cy7, and anti-CD8-PerCP
antibody (Biolegend, San Diego, USA).
HLA class II tetramers. HLA class II tetramers were
produced as previously described[41]. Briefly, recombinant
HLA-DR a- and b-chains were folded in the presence of a C-
terminally hexahistidine(H6)-tagged version of the peptide in
question. The peptide-HLA class II complexes were subsequently
purified on a Ni2+ charged iminodiacetic acid column. The
resulting monomers were tetramerized with PE- or APC-
conjugated Streptavidin as described for the HLA class I tetramer
above. In vitro cultured PBMCs were incubated with PE- and
APC-conjugated HLA class II tetramers for 1 h at 37uC, 5% CO2.
The cells were washed and subsequently stained with anti-CD3-
Pacific blue and anti-CD4-PerCP antibody (Biolegend, San Diego,
USA) for 30 min. All tetramer-stained cells were analyzed by flow
cytometry on LSRII (BD Biosciences).
Prediction of epitope and HLA-restriction of T cell
responses
HLA class I-restricted CD8+ T cell responses. For each
donor, all 15mer peptides eliciting a CD8+ T cell response were
submitted to our bioinformatics predictor, HLArestrictor (www.
cbs.dtu.dk/services/HLArestrictor/), which predicts the optimal
epitopes that could bind to any of the donors HLA-A, -B, or-C
molecules of the donor in question [42].
HLA class II-restricted CD8+ T cell responses. For each
donor, all 15mer peptides eliciting a CD4+ T cell response were
submitted to our bioinformatics predictor, NetMHCIIpan (www.
cbs.dtu.dk/services/NetMHCIIpan/), which predicts the binding
of the 15mer peptide to all of the HLA-DR class II molecules
available to the donor in question, as well as the peptide core
sequence interacting with the HLA class II molecule [43].
NetMHCIIpan is currently limited to predicting peptide binding
of HLA-DR molecules.
Biochemical peptide HLA class I and HLA class II binding
assays
Peptide binding to HLA class I and II. Peptide-HLA class I
and II binding affinities were determined as previously described
[44], [45]. For HLA class I, denatured and purified recombinant
HLA class I heavy chains were diluted into a refolding buffer (tris-
maleate buffer, pH 6.6) containing b2m and graded concentra-
tions of the test peptide, and incubated for 48 h at 18uC to allow
for equilibrium to be reached. For HLA class II, denatured and
purified recombinant HLA class II a- and b-chains were diluted
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into a refolding buffer containing graded concentrations of the test
peptide, and incubated for 48 h at 18uC to allow for equilibrium to
be reached.
Complex formation was detected using a proximity-based
Luminescent Oxygen Channeling Immunoassay assay and the
peptide concentration leading to half-saturation (ED50) was
determined as previously described [44], [45]. Under the limited
receptor concentrations used here, the ED50 reflects the affinity of
the interaction.
Peptide-HLA class I Stability Measurements
The stability of peptide-HLA class I complexes was measured
using 125I radiolabelled b2m in a scintillation proximity assay as
previously described [46]. Briefly, recombinant, biotinylated HLA
class I heavy chains were diluted into a refolding buffer containing
the test peptide and trace amounts of 125I radiolabeled b2m, and
allowed to refold at 18uC for 24 h in a Streptavidin-coated
scintillation microplate (Flashplate PLUS, Perkin Elmer, Boston,
MA). Dissociation was initiated by adding excess of unlabeled b2m
and placing the microplate in a scintillation counter (TopCount
NXT, Packard) adjusted to 37uC. The microplate was read
continuously for 24 h thereby allowing the dissociation of
radiolabeled b2m to be determined.
Results
Exemplifying the epitope screening strategy
Fifteen amino acid long peptides overlapping by 10 amino acids
were used to scan through the entire HCMV-derived IE1 and IE2
protein sequences. This choice of peptide size and overlap was
aimed at optimizing the chances of detecting both CD4+ T cell
responses, which preferably recognize longer peptides, and CD8+
T cell responses, which preferably recognize shorter derivatives
generated during the cell culture[47]. Using functional T cell read-
outs to identify peptides of interest, this should result in a complete
search for CD4+ and CD8+ T cell epitopes.
Initially, PBMCs from healthy donors were screened for
HCMV-specific CD4+ and CD8+ T cell responses by an ex vivo
ICS assay using pools of peptides derived from the dominant
HCMV proteins pp65, IE1, or IE2 as targets. Sixteen donors who
showed positive CD4+ and/or CD8+ T cell responses against at
least one of these peptide pools were selected for this study
(Table 1). In terms of overall cellular HCMV responsiveness (i.e.
delivering either a CD4+ or CD8+ T cell response); three of the 16
(19%) donors recognized one of the three antigens; nine (56%)
recognized two of the antigens; and four (25%) recognized all three
antigens. In terms of protein antigens, IE1 was recognized by 15
(94%) of the donors (predominantly by CD8+ T cells), pp65 was
recognized by 13 (81%) of the donors (equally distributed between
CD4+ and CD8+ T cell responses), and IE2 was recognized by five
(31%) of the donors (predominantly by CD4+ T cells).
Sequence-based typing including all three loci encoding HLA
class I molecules (HLA-A, -B, and -C) and all six loci encoding
variable HLA class II molecules (HLA-DRB1, -DRB3/4/5, -
DQA1, -DQB1, -DPA1 and -DPB1) were used to perform high-
resolution HLA typing of the 16 donors (Table 1). These donors
represent some of the most frequent HLA-types in the Caucasian
population in Northern Europe ([48] and unpublished observa-
tions).
Having established that our cohort of donors all harbored
HCMV-specific cellular immune responses we started screening
for peptide-specific responses. We used two cellular assays,
ELISpot and ICS, each with unique advantages and disadvan-
tages. Whereas an ELISpot assay may be sensitive enough to
capture ex vivo cellular responses, an ICS assay is less sensitive and
may require in vitro culture and restimulation. On the other hand,
an ICS assay can readily distinguish between CD4+ and CD8+ T
cell responses. Using a multi-step procedure we combined the
advantages of two assays: the ELISpot assay was initially used to
identify individual ex vivo recognized peptides, next relevant
peptides were used to expand the corresponding T cells in vitro,
and then the ICS assay was used to characterize the expanded T
cells identifying their peptide-specificity and CD4 or CD8
phenotype (this strategy is outlined in Figure 1, blue boxes). The
combined screening procedure is illustrated here using donor 33,
since this donor showed both CD4+ and CD8+ T cell reactivity,
and had the added advantage of being homozygous, thus reducing
the complexity of the HLA molecules involved in this example.
According to the ex vivo ELISpot screening, donor 33 recognized
four peptides: three IE1 peptides (IE186–100, IE191–105 and IE1196–
210) and one IE2 peptide (IE2356–370) (Figure 2A). PBMCs were
briefly in vitro cultured and expanded with a pool of these four
peptides, and harvested. The cells were subsequently analyzed by
ICS for CD4+ and CD8+ T cell recognition of the individual
peptides: one peptide (IE1196–210) was only recognized by CD8
+ T
cells, another peptide (IE186–100) was recognized by both CD4
+
and CD8+ T cells, and two peptides (IE191–105 and IE2356–370)
were only recognized by CD4+ T cells (Figure 2B).
The ideal way to identify and validate the epitope-specific,
HLA-restricted specificity of a T cell response, would be to label
the T cells with specific HLA tetramers; peptide-HLA class I
tetramers for CD8+ T cell responses, and peptide-HLA class II
tetramers for CD4+ T cell responses (the strategies for the
generation of appropriate HLA class I and II tetramers are
outlined in Figure 1, green and red boxes, respectively). To
generate appropriate peptide-HLA class I tetramers one would
have to identify the proper peptide-MHC combination recognized
by the T cell in question. A priori, any submer peptide (e.g. 8-, 9-,
10-, and 11mers), that potentially could be generated from a given
15mer peptide and bind to any of the donor’s HLA class I
molecules, could be involved. Our recently described bioinfor-
matics predictor, HLArestrictor [42], aims at simplifying this
process by predicting which combinations of submer peptide and
available HLA class I molecule are the most likely T cell receptor
ligands. In this case, CD8+ T cells from donor 33 with HLA-
A*01:01, -B*08:01, and -C*07:01 recognized the two 15mer
peptides IE186–100 and IE1196–210. The highest-ranking peptide-
HLA combinations predicted for the 15mer peptide IE1196–210
was the 9mer IE1199–207-HLA-B*08:01, with a percentile rank of
the predicted affinity of 0.1 (i.e. less than 1 out of 1000 random
peptides are predicted to bind with better affinity). Among the
highest-ranking peptide-HLA combinations predicted for the
15mer peptide IE186–100 was the 8mer IE188–95-HLA-B*08:01
and 9mer IE188–96-HLA-B*08:01 with percentile ranks of
predicted binding affinities of 1.5 and 3.0, respectively. These
three submer peptides were synthesized and their binding status
were validated in a biochemical peptide-HLA class I binding assay
(Table 2). Conventionally, a threshold of 500 nM affinity is
expected for MHC class I-restricted epitopes (however, we have
noted that the peptide-binding affinities to our recombinant HLA-
B*08:01 is lower than for most other HLA class I molecules, and
we are currently trying to understand whether this is an artifact of
the recombinant molecules, or a real phenomenon). Although low,
these binding affinities were sufficient to support folding and
tetramer production for the IE188–96-HLA-B*08:01 combination.
In vitro restimulated CD8+ T cells from donor 33 responded to
IE188–96, but not to IE188–95 (Figure 3A). Finally, the epitope and
restriction specificities could be validated by ex vivo tetramer
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staining of PBMCs from donor 33. Both IE188–96-HLA-B*08:01
and IE1198–207-HLA-B*08:01 tetramers labeled a high frequency
of the CD8+ T cells: 8.4% were labeled by IE188–96-HLA-B*08:01
and 1.5% by IE1198–207-HLA-B*08:01 (Table 2; Figure 3B and C).
Thus, the specificities of both CD8+ T cell responses identified in
donor 33 had been defined and validated. Each peptide
represented a CD8+ T cell epitope restricted by HLA-B*08:01.
To generate appropriate peptide-HLA class II tetramers one
would have to identify which of the HLA class II molecules
available to the donor could serve as restriction element(s).
Whereas the design of HLA class I tetramers also included an
identification of the optimal peptide, a similar step was not needed
for the design of HLA class II tetramers since longer peptides can
extend out of the HLA class II molecule at either end of the
peptide-binding cleft. Our prediction tool NetMHCIIpan [43] was
used to predict the most likely HLA class II restriction element(s)
for the identified CD4+ T cell epitopes. In addition, the identified
peptides were evaluated for binding to the available HLA class II
molecules of the donor in a biochemical peptide-HLA class II
binding assay. At this point the technologies for HLA class II
production, peptide binding analysis and predictions are more
mature for the HLA-DR molecules, than for HLA-DQ and -DP
molecules. In addition, we have recently developed an HLA class
II tetramer protocol employing H6-tagged peptides for purification
purposes, which has been validated for several HLA-DR
molecules[41]. Thus, out of necessity and practicality, we have
focused our HLA class II restriction analysis on HLA-DR
molecules.
Donor 33 had CD4+ T cell responses directed against three
peptides: two overlapping peptides, IE186–100 and IE191–105, and a
singular peptide, IE2356–370. These were evaluated for binding to
the two HLA-DR molecules of this donor (Table 3). The two
overlapping peptides IE186–100 and IE191–105 were both predicted
and measured to be high affinity binders to HLA-DRB1*03:01
(measured binding affinities of 4 nM and 10 nM, respectively),
and both supported tetramer generation. Since CD4+ T cells tend
to be present at low frequencies[49], PBMCs were in vitro
expanded before labeling them with HLA class II tetramers. Both
overlapping tetramers labeled expanded CD4+ T cells: IE186–100-
HLA-DRB1*03:01 tetramers labeled 2.7% and IE191–105-
DRB1*03:01 tetramers labeled 3.8% of the CD4+ T cells
(Figure 4A and B). One of the overlapping peptides, IE186–100,
also bound to HLA-DRB3*01:01 and supported tetramer
generation, but no IE186–100-HLA-DRB3*01:01 tetramer labeling
Table 1. Donor demographics.
Ex Vivo T cell responses Class I Class II
Donor#
pp65 CD4/
8 IE1 CD4/8 IE2 CD4/8 HLA-A HLA-B HLA-C DRB1 DRB3, 4, 5 DQA1 DQB1 DPA1 DPB1
1 +/+ 2/+ 2/2 02:01,
03:01
35:01,
44:02
04:01,
05:01
01:01,
11:01
3*02:02 01:01, 05:05 03:01,
05:01
01:03 04:01
5 +/+ 2/+ 2/+ 01:01,
24:02
37:01,
39:06
06:02,
07:02
15:01 5*01:01 01:02 06:02 02:01 10:01,
11:01
8 +/+ 2/+ 2/2 11:01 55:01,
35:01
03:03,
04:01
01:01,
15:01
5*01:01 01:01, 01:02 05:01,
06:02
01:03 04:01,
04:02
13 2/+ 2/+ 2/2 02:01 39:01,
44:02
07:02,
07:04
07:01,
15:01
4*01:03,
5*01:01
01:02, 02:01 03:03,
06:02
01:03 04:01
14 2/2 2/+ +/2 01:01,
02:01
08:01,
37:01
06:02,
07:01
03:01,
09:01
3*01:01,
4*01:03
03:02, 05:01 02:01,
03:03
01:03 04:01
19 2/2 2/+ 2/2 01:01,
02:01
08:01,
40:01
03:04,
07:01
03:01,
13:02
3*01:01,
3*03:01
01:02, 05:01 02:01,
06:04
01:XX 04:01
22 +/+ +/2 2/2 11:01,
32:06
13:02,
15:17
06:02,
07:01
07:01,
13:01
3*01:01,
4*01:03
01:03, 02:01 02:02,
06:03
01:03,
02:01
04:01,
17:01
23 +/+ 2/+ +/2 01:01,
24:02
07:02,
08:01
07:01,
07:02
01:01,
03:01
3*01:01 01:01, 05:01 02:01,
05:01
01:03 04:01
26 +/2 2/2 2/2 01:01,
03:01
08:01,
27:05
02:02,
07:01
01:01,
04:01
4*01:03 01:01, 03:01 03:01,
05:01
01:03 04:01
28 +/2 +/+ 2/2 03:01,
26:01
07:02,
14:01
07:02,
08:02
07:01,
08:03
4*01:01 02:01, 06:01 02:02,
03:01
01:03 02:01,
04:02
29 +/+ +/+ 2/2 03:01,
11:01
13:02 06:02 07:01,
13:02
3*03:01,
4*01:03
01:02, 02:01 02:02,
06:04
01:03 04:01,
04:02
33 +/2 +/+ +/2 01:01 08:01 07:01 03:01 3*01:01 05:01 02:01 01:03 04:01
38 2/+ 2/+ 2/2 29:02,
68:01
44:02,
45:01
06:02,
07:04
07:01,
11:01
3*02:02,
4*01:01
02:01, 0505 02:02,
03:01
01:03 02:01,
04:02
40 2/+ 2/+ 2/2 01:01,
24:02
07:02,
39:06
07:02 01:01,
15:01
5*01:01 01:01, 01:02 05:01,
06:02
01:03 04:01,
04:02
41 +/2 +/2 +/2 01:01,
24:02
08:01,
38:01
07:01,
12:03
03:01,
07:01
3*01:01,
4*01:01
02:01, 05:01 02:01,
02:02
02:01 01:01,
11:01
44 2/2 2/+ 2/2 01:01,
24:02
37:01,
40:01
03:04,
06:02
04:04,
08:01
4*01:03 03:01, 04:02 03:02,
04:02
01:03 02:01,
03:01
T cell responses were determined using ex vivo ICS. + denotes T cell response, - denotes no T cell response.
doi:10.1371/journal.pone.0094892.t001
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of CD4+ T cells could be detected (Table 3). In addition to
predicting the binding affinity between a given peptide and an
HLA class II molecule, NetMHCIIpan also predicts the core
sequence of the peptide interacting with the HLA class II
molecule. Thus, peptides IE186–100 and IE191–105 were predicted
to bind to HLA-DRB1*03:01 through the same core sequence
(VRVDMVRHR). This raises the possibility that it might be the
same, or largely overlapping, T cell populations that recognize the
two complexes. To determine this, the cells were double labeled
with PE-labeled IE186–100-HLA-DRB1*03:01 and APC-labeled
IE191–105-HLA-DRB1*03:01 (Figure 4C). Labeling with the
IE186–100-HLA-DRB1*03:01 tetramer indicates that there are at
least two CD4+ T cell populations recognizing the epitope with
different affinities (Figure 4A). The double labeling splits this up
even further since there are at least four different CD4+ T cell
populations recognizing the two epitopes with different affinities as
judged by their staining intensities: One population (0.9%)
recognizing only the IE191–105-DRB1*03:01 epitope, two popula-
tions accounting for the majority of the CD4+ T cells (2% and
0.7%), which recognize both epitopes with different affinities, and
one very small population (0.1%) recognizing only the IE186–100-
DRB1*03:01 epitope (Figure 4C). During processing of an epitope
various sizes might be produced that all bind through the same
core sequence with various flanking sequences that can stimulate
different T cell clones thereby broadening the T cell repertoire,
which in principal could recognize the same epitope[50].
The third peptide, IE2356–370, was a high affinity binder
(KD,50 nM) to both DRB1*03:01 and DRB3*01:01 (Table 3).
Subsequent tetramer labeling showed that the CD4+ T cells
predominantly recognized IE2356–370 presented by HLA-
DRB1*03:01 (labeling 6.8% of the expanded CD4+ T cells) and
to a lesser extent IE2356–370 presented by HLA-DRB3*01:01
(0.2%) (Figure 4D and E). Tetramer double staining analysis
revealed that the latter tetramer labeling could be fully accounted
for by a small CD4+ T cell population that cross-recognized the
epitope presented by both DRB1*03:01 and DRB3*01:01
Figure 1. Overview of screening strategy. PBMCs were screened by ex vivo ELISpot analysis for recognition of 187 overlapping 15mer peptides
spanning the entire IE1 and IE2. Pools of positively recognized peptides were used to expand the T cells for 12–14 days and subsequently analyzed
for CD4+ and CD8+ T cell recognition using ICS and flow cytometric analysis. CD4+ T cell epitope deconvolution: The recognized 15mer peptide and the
donor’s HLA class II molecules were submitted to NetMHCIIpan to predict the HLA class II restriction element and the peptide core sequence
interacting with the HLA class II molecule. The interaction was subsequently validated using a biochemical HLA class II binding assay. For a selection
of the recognized epitopes, H6-tagged peptides were produced and used to generate peptide-HLA class II tetramers, which were subsequently used
for validation of T cell specificity and HLA class II restriction. CD8+ T cell epitope deconvolution: The 15mer peptides recognized by a given donor
together with the donors HLA class I molecules were submitted to the HLArestrictor to predict the optimal size epitope and HLA-restriction.
Interaction between the predicted epitope and HLA class I molecule was validated by biochemical affinity- and stability assays. The T cell specificity
and HLA class I restriction was validated by peptide-HLA class I tetramer staining.
doi:10.1371/journal.pone.0094892.g001
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(Figure 4F). Note, that the two HLA-DR molecules were predicted
to bind the same core sequence of the peptide, which could explain
how a small CD4+ T cell population could recognize the same
peptide in the context of two different HLA-DR molecules
(Table 3).
Thus, the specificities of all three CD4+ T cell responses
identified in donor 33 had been defined and validated. The
overlapping peptides IE186–100 and IE191–105 represented one
epitope presented by one HLA-DR molecule, HLA-DRB1*03:01.
The remaining peptide, IE2356–370, represented one epitope
presented by two HLA-DR molecules; primarily by HLA-
DRB1*03:01 and to lesser extent by HLA-DRB3*01:01. Note
that no attempts to map these CD4+ responses to HLA-DQ or -
DP have been made, and that we cannot exclude the existence of
additional CD4+ T cell responses restricted to these HLA class II
isotypes.
Figure 2. ELISpot and ICS analysis of donor 33. PBMCs were initially screened by ex vivo ELISpot and the CD4+ and CD8+ T cell recognition
subsequently determined by ICS analysis. Donor 33 recognized four different peptides, which are indicated above the results. A) Ex vivo IFN-c ELISpot
assay. Spot forming units (SFU) are indicated as positive spots per 106 PBMCs. B) ICS analysis of T cells expanded on the identified 15mers. FACS plots
show gated CD3+ T cells. The elicited frequency is indicated. Pink indicates responding CD8+ T cells. Green indicates responding CD4+ T cells.
doi:10.1371/journal.pone.0094892.g002
Figure 3. Donor 33 - CD8+ T cell epitope validation. CD8+ T cell responses were detected against the 15mers IE186–110 and IE1196–210. In IE186–
110 two B*08:01 binding optimal peptides, IE188–95 and IE188–96, were predicted, while in IE1196–210 one B*08:01-restricted optimal peptide IE1198–207,
was predicted. A) ICS analysis of predicted optimal peptides: Chart showing IFN-c responses following restimulation of in vitro cultured PBMCs with
graded doses of IE188–95 and IE188–96. B) Optimal epitope and HLA class I restriction validated by ex vivo peptide-HLA class I tetramer staining with the
IE188–96-HLA-B*08:01 tetramer. C) Optimal epitope and HLA class I restriction validated by ex vivo peptide-HLA class I tetramer staining with the
IE1199–207-HLA-B*08:01 tetramer. The plots show gated CD3
+ T cells; frequencies of tetramer-positive CD8+ T cells (boxed-in and pink) are indicated.
doi:10.1371/journal.pone.0094892.g003
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Extending the identification of CD8+ T cell epitopes to all
donors
The study was subsequently extended to 15 additional donors,
who were screened for recognition of the 187 overlapping IE1 and
IE2 peptides. The initial ELISpot screening revealed that each
donor recognized from zero to 15 of the overlapping IE1 and IE2
peptides (data not shown)). The subsequent ICS analysis of in vitro
stimulated and cultured T cells showed that per donor zero to six
15mer peptides elicited CD8+ T cell responses (one donor, donor
26, did not have any detectable anti-IE1 or -IE2 CD8+ T cell
responses), whereas two to ten 15mer peptides elicited CD4+ T cell
responses (Table 4). Three donors recognized CD8+ T cell
epitopes located within the initial 85 amino acid sequence, which
is identical in IE1 and IE2, but somewhat surprisingly, none of the
donors recognized CD8+ T cell epitopes located within the unique
part of IE2 (Table 4).
In the 16 donors, a total of 44 CD8+ T cell responses were
observed against 16 different HCMV-derived IE1 and/or IE2
peptides. For each peptide, the peptide sequence and the HLA
class I molecules of each responding donor were submitted to the
HLArestrictor, which then suggested the most likely peptide-HLA
class I combinations. Shared HLA class I molecules between the
responding donors were taken into account when selecting which
predicted epitopes should be synthesized. Once these peptides had
been acquired, they were analyzed for binding to the suggested
HLA class I restriction elements, and for the stability of the
resulting peptide-HLA class I complexes (stability has been
suggested to be a better correlate of immunogenicity than affinity
[51]). For all productive interactions, peptide-HLA class I
tetramers were generated and used to label relevant CD8+ T
cells. The 16 overlapping peptides gave rise to 14 different
tetramer validated CD8+ T cell epitopes covering 11 different
HLA class I restriction elements (three of the epitopes were found
in overlapping peptides and one 15mer peptide contained two
epitopes, an 8mer and 9mer, restricted by two different HLA class
I molecules, B*08:01 and C*06:02, thus accounting for all 16
overlapping peptides) (Table 5; several epitopes have been
described elsewhere[52], [53], [54], [55], [56], [57], [58], [59],
[60], [61]). Twelve of the 14 validated CD8 epitopes represented
interactions with a half-life longer than 1 h (Table 5) emphasizing
the importance of peptide-HLA class I stability in defining
immunogenicity. In total, 44 of 44 (100%) CD8+ T cell responses
that had been detected by the combined ELISpot/ICS approach
were explained and validated at the level of tetramer labeling.
Extending the identification of CD4+ T cell epitopes to all
donors
In the 16 donors, a total of 81 CD4+ T cell responses were
observed against 28 different HCMV peptides derived from IE1
and/or IE2; 14 of the 28 peptides were derived from IE1 (some
have previously been described[41], [62], [63], [64]) and 14 from
IE2, and all donors responded with an almost equal distribution of
IE1 and IE2 epitopes (Table 4). Many of the peptides (16 of 28)
were recognized in two or more of the 16 donors. To evaluate the
possible HLA class II restriction elements we focused on the HLA-
DR isotype due to the availability of predictions and measure-
ments of peptide-binding, and the possibility of generating HLA
class II tetramers. This is also appropriate from a functional
perspective since 89% of reported HLA class II restrictions have
been HLA-DR-restricted (IEDB, August 2013). Thus, all peptide-
HLA-DR combinations were submitted to the NetMHCIIpan
predictor to identify the most likely HLA-DR restriction element
and to identify the core sequence involved in HLA-DR binding;
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and peptide-HLA-DR binding was measured whenever possible
(the 16 donors had 18 different HLA-DR molecules in total; 14 of
these were available for binding analysis). The predicted and/or
measured binding between the recognized peptide and the HLA-
DR molecules are shown in Tables S1 and S2. In accordance with
the general assumption that HLA class II molecules are more
promiscuous than HLA class I molecules [65], several peptides
bound strongly to multiple HLA-DR-molecules or were predicted
to do so. For each peptide in these tables, we have underlined the
most likely peptide-HLA class II combination(s) based on high
binding affinity (we have arbitrarily chosen a binding cut-off of
500 nM) and whether the HLA class II molecule was shared
between several responding donors.
In several cases, the above analysis still left multiple HLA class II
molecules as being possible restriction elements. An ideal way to
resolve the specificity of CD4+ T cells is to use HLA class II
tetramers, however, the availability of HLA class II tetramers is
quite limited. We have recently developed a ‘‘tagged peptide’’
approach to HLA class II tetramer generation. Guided by peptide-
HLA-DR affinity and by shared HLA-DR molecules within the
responding donors, we generated peptide-HLA DR tetramers for a
limited number of the most frequently recognized epitopes. Thus,
10 peptides were selected and produced as H6-tagged peptides for
HLA-DR tetramer production. Using these tetramers we success-
fully validated the HLA class II restriction for eight of the 28
15mer peptides that elicited CD4+ T cell responses (also included
in Tables S1 and S2, and summarized in Table 6). This limited
panel of peptide-HLA-DR combinations included at least seven
epitopes (using core sequences as an approximation, the following
epitopes were identified: VRVDMVRHR, IKEHMLKKY,
FTKNSAFPK, VKIDEVSRM, QIIYTRNHE, IIYTRNHEV,
and FLMEHTMPV) and seven different HLA-DR molecules
(HLA-DRB1*01:01, -DRB1*03:01, -DRB1*07:01, -DRB1*13:01,
-DRB1*15:01, DRB3*01:01, and -DRB5*01:01) allowing tetra-
mer validation of 39 of the 81 observed CD4+ responses. In the
Figure 4. Donor 33 - CD4+ T cell epitope validation. Three different 15mers elicited CD4+ T cell responses, IE186–100, IE191–105, and IE2356–370 in
donor 33. T cells were expanded for 12 days on a mix of the three peptides. The specificity and HLA class II restriction of the CD4+ T cell responses
were evaluated using peptide-HLA class II tetramers. The cells were stained with anti-CD3, -CD4, and the peptide-HLA class II tetramers either alone or
in combination. IE186–100 and IE191–105 are overlapping peptides and bind to the same DRB1*03:01. The cells are stained in A) with the IE186–100-
DRB1*03:01 tetramer, in B) with the IE191–105-DRB1*03:01 tetramer, and in C) with a combination of PE-labeled IE186–100-DRB1*03:01 and APC-labeled
IE191–105-DRB1*03:01 tetramer. The IE2356–370 peptide binds to both of the donor’s HLA-DR molecules, DRB1*03:01 and DRB3*01:01. The cells are
stained in D) with the IE2356–370-DRB1*03:01 tetramer, in E) the IE2356–370-DRB3*01:01 tetramer, and in F) with a combination of PE-labeled IE2356–370-
DRB1*03:01 and APC-labeled IE2356–370-DRB3*01:01 tetramer. The plots show gated CD3
+ T cells, and the frequency of tetramer-positive CD4+ T cells
(boxed-in and green) is indicated.
doi:10.1371/journal.pone.0094892.g004
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future, we expect more CD4+ T cell responses to be tetramer
validated as HLA class II tetramers become more widely available.
Discussion
The IE1 and IE2 proteins are among the first to be expressed
during HCMV infection and reactivation. These proteins may
therefore be particularly valuable targets for an immune based
prevention and/or treatment strategy against HCMV. A priori, an
approach exploiting multiple epitopes, multiple HLA restriction
elements, and encompassing both CD8+ and CD4+ T cell
responses, should stand a better chance of generating a robust,
long-lived response and avoid virus escape. Here, we have used
187 overlapping peptides representing the complete 412 and 580
amino acid long IE1 and IE2 protein sequences, respectively, to
investigate the spectrum of IE1- and IE2-specific T cell responses
in human donors. Examining 16 HCMV-reactive donors, we
identified a total of 44 CD8+ T cell responses involving 16
peptides, and 81 CD4+ T cell responses involving 28 overlapping
peptides (corresponding to about three CD8+ and 5 CD4+ T cell
responses per donor per 1000 amino acids). These peptides were
then analyzed by peptide-HLA class I or II binding predictions
and/or measurements suggesting suitable peptide-HLA combina-
tions for subsequent investigations. Whenever possible, relevant
peptide-HLA tetramers were generated and used to examine and
validate the peptide-specific, HLA-restricted nature of the
observed T cell reactivities.
All CD8+ T cell epitopes found in the initial screen could
eventually be identified and validated at the tetramer level. Several
factors contributed to this success rate. With current technology, it
was feasible to acquire a systematic set of overlapping peptides
representing the entire IE1 and IE2 proteins. It was also feasible to
obtain sufficient numbers of donor T cells to test T cell responses
against these proteins. This allowed us to use functional T cell
assays such as ELISpot and/or ICS as the initial epitope screen.
Only then were biochemical (in particular peptide-HLA class I
stability measurements) and bioinformatics approaches used to
search for T cell epitopes within the overlapping 15mer peptides
that gave a positive hit in the initial screen, and to search for their
HLA restriction elements. This strategy of using a functional
screen first and a bioinformatics screen second has the advantage
that it avoids many of the false positives that plague peptide-HLA
predictors when they are used as the initial screen. Under these
conditions, the HLArestrictor proved to be a very efficient tool to
identify CD8+ T cell epitopes and their HLA restriction elements.
In about 90% of the T cell responses found in the initial screen, the
HLArestrictor successfully identified the peptide-HLA combina-
tion that later could be validated by HLA tetramer analysis; in
fact, in 65% it was the very first choice of the HLArestrictor. The
output from the HLArestrictor was used to select new peptides for
synthesis as putative CD8+ T cell epitopes and then to generate the
corresponding peptide-HLA class I tetramers, which were used to
validate the proper CD8+ T cell epitopes. Here, we successfully
used our ‘‘one-pot, mix-and-read’’ HLA class I tetramer technol-
ogy[40] to generate 14 HLA class I tetramers covering 11 different
HLA class I molecules. Thus, we have established a highly efficient
mode of CD8+ T cell discovery suitable for smaller target antigens.
This approach would even be suitable for a small virus proteome
of a few thousand amino acids; however, with current technologies
both the costs of peptides and the limited size of donor samples
prohibit the application of this approach to T cell epitope
discovery involving larger challenges (e.g. above large viral
proteomes). Extending this highly efficient approach to larger
challenges would require that future technologies manage to
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miniaturize the initial functional screen e.g. through peptide or
peptide-HLA microarrays[66], [67], [68], [69], [70]. One
potential drawback of our strategy is that we might miss low
frequency epitopes that are not detectable by the ex vivo ELISpot
analysis as well as the occasional CD8 epitopes that cannot be
efficiently generated by processing during the in vitro culture of the
15mer peptide[71]. Some of the results gave rise to redefinitions of
previously published epitopes in terms of peptide-length and/or
HLA restriction (see File S1).
In contrast to the high success rate of our CD8+ T cell discovery
strategy, only about half of the CD4+ T cell responses could be
explained and validated at the level of peptide-HLA class II
tetramers (Tables S1 and S2). This is in line with the notion that
HLA class I technologies currently are more mature with more
accurate predictions[72], [73], having better coverage with respect
to predicting and measuring peptide-binding to HLA class I, and
better availability of HLA class I tetramers than the corresponding
HLA class II technologies[40], [42], [43], [44], [46], [74], [75].
Thus, the exact identification of the specificity of a CD4+ T cell
response can be quite cumbersome. In particular, it is not trivial to
establish which HLA class II molecule is involved as restriction
element in a given CD4+ T cell response. This is often inferred
based on more or less indirect assays such as predictions or
measurements of peptide-HLA class II interactions, the inhibition
mediated by antibodies specific for known HLA iso- or allo-types,
presentation by HLA matched or unmatched cell lines etc. The
latter is indeed the path taken by Sette and coworkers, who
recognized that the problems of establishing HLA class II
restrictions are so manifest, that they recently established a panel
of 46 single-transfected cell lines with the primary purpose of
allowing accurate determination of HLA class II restriction[76].
The interpretation of these indirect assays is complicated by the
promiscuous nature of peptide binding to HLA class II and of T
cell recognition as exemplified here. Thus, two epitopes were
presented in the context of more than one restriction element (e.g.
IE191–105 with DRB1*03:01 and DRB1*13:01; IE2408–422 with
DRB1*07:01 and DRB1*15:01); and different extensions of the
same core-peptide presented by the same HLA class II molecule,
as well as the same peptide presented by different HLA class II
molecules, were seen by some T cells as being identical, yet by
other T cells as being dissimilar (see Figure 4C and 4F). Ideally,
one would like to use peptide-HLA class II tetramers to identify
and validate CD4+ T cell epitopes. Here, we have used our
recently reported HLA class II tetramer technology[41] to
generate peptide-HLA class II tetramers. This allowed us to
validate about half of the observed CD4+ T cell responses
(Table 6). At this time, our availability of HLA class II tetramers is
limited to HLA-DR molecules. For 25 of the 28 peptides that
stimulated CD4+ T cell responses we were able to suggest an
HLA-DR restriction element. No HLA-DR binding could be
detected for the remaining three peptides (IE1429–448, IE1449–463
and IE1453–468). These cases could represent CD4
+ T cell
responses that are restricted to HLA-DQ or -DP molecules.
These examples emphasize the need for extending efficient
bioinformatics, immunochemistry, and tetramer technologies to
these isotypes, too.
The phenomenon that two overlapping peptides both stimulat-
ed a CD4+ T cell response in the same donor was a very frequent
observation (IE181–95 /IE186–100; IE186–100/IE191–105; IE191–105/
IE196–110; IE1449–463/IE1453–468; IE2151–165/IE2156–170; IE2383–
397/IE2388–402; IE2438–452/IE2443–457; and IE2558–572/IE2563–577).
As exemplified here, these overlapping pairs may represent one
and the same epitope being present in both overlapping peptides.
Alternatively, they may represent two different epitopes. As
illustrated here double labeling using tetramers corresponding to
each of the overlapping peptides should be able to validate
Table 4. IE1 and IE2 T cell responses identified per donor.
IE1/IE2 shared segment Unique IE1 segment Unique IE2 segment IE total
Donor# CD4 CD8 CD4 CD8 CD4 CD8 CD4 CD8
1 0 0 0 3 4 0 4 3
5 0 0 4 3 2 0 6 3
8 0 0 1 1 3 0 4 1
13 0 0 1 1 1 0 2 1
14 0 0 3 3 5 0 8 3
19 0 2 2 4 1 0 3 6
22 0 0 6 3 1 0 7 3
23 0 0 5 1 5 0 10 1
26 0 0 0 0 2 0 2 0
28 0 0 2 2 2 0 4 2
29 0 0 4 5 4 0 8 5
33 0 0 2 2 1 0 3 2
38 0 1 2 2 3 0 5 3
40 0 0 1 1 3 0 4 1
41 0 0 7 4 3 0 10 4
44 0 2 1 4 0 0 1 6
Total 0 5 41 39 40 0 81 44
Sixteen donors were evaluated for CD4+ and CD8+ T cell recognition of overlapping IE1 and IE2 peptides. The initial segment of IE1 and IE2 (85 amino acids) is identical
and thus the proteins have been divided in three segments: shared IE1 and IE2, unique IE1, and unique IE2. T cell responses are shown in terms of ICS validated
responses against individual 15mer peptides
doi:10.1371/journal.pone.0094892.t004
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whether overlapping responses represented a single unifying
specificity, or two distinct specificities. Ideally, such cross-reactions
should be captured and indicated by the core sequences suggested
by the NetMHCIIpan predictor. Indeed, the same core-sequences
were suggested for IE186–100 and IE191–105 binding to HLA-
DRB1*03:01 (Table 6 and Table S1), which were cross-recognized
(Figure 4C) as well as for the IE2356–370 peptide binding to both
HLA-DRB1*03:01 and HLA-DRB3*01:01 (Table 6 and Table
S2), which were also cross-recognized (Figure 4F).
Some of the HLA class II epitopes were recognized very
frequently in our donors. A single epitope, IE2408–422, was
recognized in 10 of the 16 donors (Table S2). Three donors,
who expressed HLA-DRB1*15:01, all had CD4+ T cells with
tetramer validated specificity for IE2408–422 presented by HLA-
DRB1*15:01, and six donors, who expressed HLA-DRB1*07:01,
had CD4+ T cells with tetramer validated specificity for IE2408–422
presented by HLA-DRB1*07:01. Of note, one donor had CD4+ T
cells recognizing IE2408–422 presented by both HLA-DRB1*07:01
and HLA-DRB1*15:01, and in two donors we were not able to
determine the restriction element(s). Tetramers with the IE2408–422
epitope were also synthesized with HLA-DRB1*01:01, HLA-
DRB1*03:01, HLA-DRB1*11:01, HLA-DRB1*13:01, HLA-
DRB4*03:01, and HLA-DRB5*01:01, but these did not label
CD4+ T cells in relevant donors. A cluster of four overlapping IE1
peptides covering amino acid 81 to 110 in IE1 were recognized in
seven donors. These epitopes appeared in pairs of two overlapping
peptides (i.e. the overlapping IE181–95 and IE186–100 epitopes were
recognized by two donors, the overlapping IE186–100 and IE191–
105 epitopes were recognized by five donors, and the overlapping
IE191–105 and IE196–110 epitopes were recognized by one donor)
(Table S2). The two donors, who recognized the overlapping
IE181–95 and IE186–100 peptides, shared HLA-DRB4*01:03, -
DRB1*13:01 and -DRB1*13:02, all of which, from a peptide
binding point of view, could serve as restriction elements. The five
donors, who recognized the overlapping IE186–100 and IE191–105
peptides, shared HLA-DRB1*03:01, which bound both peptides
with high affinity. PBMCs from all five donors could be labeled
with HLA class II tetramers generated with HLA-DRB1*03:01
and peptides IE186–100 or IE191–105. Labeling the PBMCs with
both tetramers revealed that we are dealing with a dominant TcR
specificity, which reacts with both tetramers, and minor popula-
tions, which react with only one of the two tetramers (see Figure 4C
for donor 33, who was one of these five donors). In agreement with
the dominant shared specificity, the NetMHCIIpan predictor
identified the same core sequence from the two overlapping
peptides. The one donor, who recognized the overlapping IE191–
105 and IE196–110 peptides, expressed one HLA class II molecule
that was predicted and measured to be a binder of both peptides:
HLA-DRB1*13:01. The two corresponding tetramers, IE191–105 -
DRB1*13:01 and IE196–110-DRB1*13:01, were generated and the
majority of the CD4+ T cells appeared to react with both
tetramers. In this case, however, the NetMHCIIpan predictor
suggested different core sequences from the two overlapping
peptides.
In a landmark study by Sylwester and coworkers, who analyzed
the immunogenicity of 213 HCMV open reading frames, IE1 and
IE2 were among the most immunogenic proteins, inducing CD4+
and or CD8+ T cell responses in a high percentage of healthy
seropositive donors. Furthermore, the average response frequen-
cies of memory CD4+ and CD8+ T cells against the two proteins
were comparable although CD4+ T cell response magnitudes
directed against IE1 and IE2 were not as strong as CD4+ T cell
responses directed against pp65[15]. Other studies [53], [56] have
not been able to reproduce the CD4+ T cell immunogenicity
against IE1 observed by Sylwester and coworkers. Our findings
are more consistent with later reports as detection of CD4+ T cell
responses against IE1 relied on ELISpot and subsequent in vitro
stimulation. This applies to IE2 as well, but here the absence of
Table 6. Summary of HLA class II tetramer validated IE1/IE2 epitopes.
Validated HLA class II restriction
Peptide Sequence Donors
Total # of
donors Restriction
Core sequence
predicted
measured
affinity (nM) Reference
IE186–100 VKQIKVRVDMVRHRI 14, 19, 23,
33, 41
5 DRB1*03:01 VRVDMVRHR 4 this paper
IE191–105 VRVDMVRHRIKEHML 14, 19, 23,
33, 41
5 DRB1*03:01 VRVDMVRHR 10 [63], [64]
22 1 DRB1*13:01 VRVDMVRHR 2
IE196–110 VRHRIKEHMLKKYTQ 22 1 DRB1*13:01 IKEHMLKKY 2 [63], [64]
IE1211–225 NIEFFTKNSAFPKTT 5, 8, 13, 40 4 DRB5*01:01 FTKNSAFPK 7 [41]
IE2356–370 TRRGRVKIDEVSRMF 14, 19, 23,
33, 41
5 DRB1*03:01 VKIDEVSRM 9 this paper
33a 1 DRB3*01:01 VKIDEVSRM 2
IE2408–422 KGIQIIYTRNHEVKS 5, 13
b, 40 3 DRB1*07:01 IIYTRNHEV 53 this paper
13b, 22,
28, 29, 38, 41
6 DRB1*15:01 QIIYTRNHE 45
IE2438–452 ALSTPFLMEHTMPVT 1, 8, 23,
26, 40
5 DRB1*01:01 FLMEHTMPV 6 this paper
IE2443–457 FLMEHTMPVTHPPEV 1, 8, 23,
26, 40
5 DRB1*01:01 FLMEHTMPV 2 this paper
a: A subpopulation of T cells could also be stained with an IE2356–370-HLA-DRB3*01:01 tetramer. This phenomenon was not observed in donor 14, 19, or 23 (donor 41 not
done).
b: T cell populations that could be labeled with IE2408–422-DRB1*07:01 or IE2408–422-DRB1*15:01 were detected.
doi:10.1371/journal.pone.0094892.t006
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apparent ex vivo immunogenicity was also observed in the CD8+ T
cell population. Numerous T cell epitopes have been identified in
IE1, most being CD8+ T cell epitopes, but also CD4+ T cell
epitopes[41], [52], [53], [54], [55], [56], [58], [59], [60], [61],
[62], [63], [64]. To our knowledge less than a handful IE2
epitopes have been published[77], [78], [79]. Here, we have found
several novel and immunodominant CD4+ and CD8+ T cell
epitopes. In IE1, we found both CD4 and CD8 epitopes, whereas
CD4+ T cell epitopes dominated in IE2. In general, each
individual donor recognized more CD4 epitopes than CD8
epitopes, but the frequencies of CD8+ T cells were higher than
the frequencies of CD4+ T cells. Involving merely 16 donors, this
study has generated information about CD4+ and CD8+ T cell
epitopes against IE1/IE2 that potentially cover 91 and 98% of the
Caucasian population, respectively (ignoring linkage disequilibri-
um). We believe that IE1 and IE2 represent a source of
particularly important HCMV-derived immune targets, and that
the information obtained here should provide important informa-
tion for future vaccine development and adoptive T cell transfer
against HCMV. Due to the detrimental effects of HCMV during
fetal development and in immunocompromised patients, generat-
ing efficient vaccines and/or immunotherapies against HCMV
remain a very high priority. We are currently addressing the
importance of these epitopes, as well as pp65 T cell epitopes, in a
longitudinal study of a cohort of patients treated with allo-HCT.
Supporting Information
Figure S1 Cysteine interferes with T cell recognition of
the IE1290–299-A*01:01 epitope. Four A*01:01
+ donors
recognize the optimal epitope IE1290–299 (TSDACMMTMY).
Binding affinity and stability measurements confirmed binding to
A*01:01, but IE1290–299-A*01:01 tetramer did not stain the CD8
+
T cells. Instead HLA-matched allo-presentation was used to
validate HLA-restriction. In A) in vitro cultured PBMCs from
donor 14 were analyzed by ICS for CD8+ T cell recognition of
IE1290–299-pulsed autologous DCs (left panel), allogeneic DCs
matched for A*01:01 only (middle panel), and allogeneic DCs with
no HLA class I match (right panel). In B) three donors were
analyzed by ex vivo ELISpot for recognition of the wild type
epitope, two variants with the internal C substituted for an A
(TSDAAMMTMY) or an S (TSDASMMTMY), and an N-
terminally truncated 9mer version of the epitope. In C) PBMCs
from donor 41 were stained ex vivo with A*01:01 tetramers of either
the wild type epitope (left) the CRA substituted epitope (middle)
or the CRS substituted epitope (right). The plots show gated
CD3+ cells, and the frequency of tetramer-positive CD8+ T cells is
indicated.
(EPS)
Table S1 Identified IE1-specific CD4+ T cell epitopes.
The high affinity binding and shared HLA class II molecules
within responding donors are underlined. a: Response includes a
CD8+ T cell epitope. b: Predicted affinity. NB: non binder; only
affinity measurements better (i.e. lower) than 1000 nM are shown,
peptides binding with an affinity above this threshold are indicated
as NB.
(EPS)
Table S2 Identified IE2-specific CD4+ T cell epitopes.
The high affinity binding and shared HLA class II molecules
within responding donors are underlined. a: Predicted affinity. b: A
subpopulation of T cells could also be stained with an IE2356–370-
HLA-DRB3*01:01 tetramer. This phenomenon was not observed
in donor 14, 19, or 23 (donor 41 not done). c: T cell populations
that could be labeled with IE2408–422-DRB1*07:01 or IE2408–422-
DRB1*15:01 were detected. d: Staining with HLA class II
tetramer was found negative. NB: non binder; only affinity
measurements better (i.e. lower) than 1000 nM are shown,
peptides binding with an affinity above this threshold are indicated
as NB.
(EPS)
File S1 A discussion of some of the results, which gave
rise to redefinitions of previously published epitopes in
terms of peptide-length and/or HLA restriction.
(DOCX)
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